Andrew Peter Thomas

USPTO Granted Patents = 47 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.5

ph-index = 16

Forward Citations = 967(Granted Patents)

Location History:

Congleton, GB (1993 - 2002)
Macclesfield Cheshire, GB (2007)
Macclesfield, GB (1998 - 2014)
Cheshire, GB (1995 - 2019)
Cambridge, GB (2017 - 2019)

Company Filing History:

Imperial Chemical Industries Limited

Astra Zeneca U.k. Limited

7. 6 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2019

Loading Chart...

Areas of Expertise:

Quinazoline Derivatives

VEGF Inhibitors

Pyrimidine Compounds

Cancer Treatment

Pyrazole Derivatives

Cyclin Dependent Kinase Inhibitors

Angiogenesis Inhibitors

Chemical Compounds

Heterocyclic Compounds

Pharmaceutical Compositions

Insulin-Like Growth Factor Modulators

Cinnoline Derivatives

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10457664 - Quinazoline derivatives as VEGF inhibitors (2019-10-29),

2. 10301267 - Compounds (2019-05-28),

3. 9688640 - Methods of treating cancer with a pyrazole derivative (2017-06-27),

4. 9040548 - Quinazoline derivatives as VEGF inhibitors (2015-05-26),

5. 8642608 - Quinazoline derivatives as VEGF inhibitors (2014-02-04),

6. 8604022 - N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof (2013-12-10),

7. 8129391 - N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof (2012-03-06),

8. RE42353 - Quinazoline derivatives and pharmaceutical compositions containing them (2011-05-09),

9. 7737149 - N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof (2010-06-15),

10. 7579349 - 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer (2009-08-25),

11. 7579344 - Pyrimidine derivatives possessing cell-cycle inhibitors activity (2009-08-25),

12. 7521453 - Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I) (2009-04-21),

13. 7485638 - Pyrimidine compounds (2009-02-03),

14. 7465728 - Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity (2008-12-16),

15. 7446105 - Pyrimidine compounds (2008-11-04),

Title: Innovations and Contributions of Andrew Peter Thomas

Introduction

Andrew Peter Thomas, based in Macclesfield, GB, is a prolific inventor with a remarkable portfolio comprising 47 patents. His work primarily focuses on significant advancements in pharmaceutical compounds, particularly targeting medical conditions such as cancer and rheumatoid arthritis.

Latest Patents

Among his noteworthy inventions are the quinazoline derivatives as VEGF inhibitors. This invention pertains to a specific formula (I) with defined properties, wherein 'm' is an integer ranging from 1 to 3, R' signifies halogeno or alkyl, and X represents —O—. The compounds are designed to inhibit the effects of Vascular Endothelial Growth Factor (VEGF), which plays a crucial role in various disease states. Furthermore, the patent outlines processes for the preparation of these compounds and their use as active ingredients in pharmaceutical compositions aimed at treating cancer.

Career Highlights

Throughout his career, Andrew has made significant contributions while working with renowned companies such as AstraZeneca and Zeneca Limited. His expertise and innovative approach have garnered him recognition within the pharmaceutical community.

Collaborations

Andrew has collaborated with several distinguished professionals in the field, including Laurent Francois Andre Hennequin and Jean-Jacques Marcel Lohmann. These partnerships have further enriched his research and development efforts, leading to innovative solutions in drug formulation and efficacy.

Conclusion

Andrew Peter Thomas exemplifies the spirit of innovation through his extensive work in developing medical formulations that address critical health challenges. His dedication to advancing pharmaceutical science continues to make a positive impact on the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.